Supplemental Material, Spyropoulos.Supplementary_14_Aug_2019_final - Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study

Spyropoulos, Alex C.; Lipardi, Concetta; Xu, Jianfeng; Lu, Wentao; Suh, Eunyoung; Yuan, Zhong; Levitan, Bennett; Sugarmann, Chiara; De Sanctis, Yoriko; Spiro, Theodore E.; Barnathan, Elliot S.; Raskob, Gary E.

doi:10.25384/SAGE.10639037.v1

Spyropoulos.Supplementary_14_Aug_2019_final.pdf (167.31 kB)

Supplemental Material, Spyropoulos.Supplementary_14_Aug_2019_final - Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study

journal contribution

posted on 2019-11-21, 13:10 authored by Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Zhong Yuan, Bennett Levitan, Chiara Sugarmann, Yoriko De Sanctis, Theodore E. Spiro, Elliot S. Barnathan, Gary E. Raskob

Supplemental Material, Spyropoulos.Supplementary_14_Aug_2019_final for Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study by Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Zhong Yuan, Bennett Levitan, Chiara Sugarmann, Yoriko De Sanctis, Theodore E. Spiro, Elliot S. Barnathan and Gary E. Raskob in Clinical and Applied Thrombosis/Hemostasis